This benchmark finding foreshadows the next phase of medicine, where technology helps clinicians quickly determine the root cause of disease so they can give patients the right treatment sooner.
Chemical compound reduces alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson’s, reducing cell stress and pointing to a new strategy for treating the disease.
A newly detected molecule that helps reduce damage from sustained loss of blood flow to cells and tissues could eventually be used to prevent collateral harm to vital organs during surgery.
